##  [Cell Therapy](/research-and-development/technology-platforms/cell-therapy "Cell Therapy") 

 Cell Therapy aims to treat diseases by restoring or altering certain sets of cells, or by using cells to carry a therapy through the body.  
 

 

## CAR-T cell therapy is currently one of Novartis' key focus areas for research and development

Individualized CAR (chimeric antigen receptor) T-cell therapy uses a patient’s own immune system to fight certain types of cancers. A patient’s T-cells are extracted and reprogrammed outside of the body to recognize and fight cancer cells and other cells expressing a particular antigen. CAR-T cell therapies are currently approved by various regulatory bodies to treat certain forms of advanced B-cell blood cancers. Novartis has a deep CAR-T pipeline. Our focus is to broaden the impact of cell therapy in oncology by going deeper in B-cell malignancies, potentially reaching patients in other hematological cancers and solid tumors and researching potential next-generation CAR-Ts that focus on new targets and utilize new technologies.



 



 ![Scientist working in a lab](/sites/novartis_com/files/styles/cta_image/public/2021-10/scientist-working-cell-gene-stein.jpg.webp?itok=o7eKiUD9 "Scientist working in a lab") 

 

##  Car-T Cell Therapy 

<p>Novartis is pioneering the way in cell and gene treatment, setting the standard in patient and caregiver support, safety and efficacy, access, and partnerships with healthcare institutions, local health authorities, and academic institutions.</p>



 

 [Learn More](/research-and-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond "Learn More") 



 

 



 





##  Cell therapy stories 

 [ 

 ![A Cell Processing Specialist at work in Novartis’ new cell and gene production facility in Stein, Switzerland.](/sites/novartis_com/files/styles/cards_50_50/public/2021-07/cell-processing-specialist-lab-image.jpg.webp?itok=Db7TmqSH "A Cell Processing Specialist at work in Novartis’ new cell and gene production facility in Stein, Switzerland.") 

 

###  Hardwiring the future 

A Cell & Gene production unit staffed by a highly trained team at Novartis will soon begin operating in Stein, Switzerland.

 

 

 ](/stories/hardwiring-future) [ 

 ![Surface of an engineered T cell](/sites/novartis_com/files/styles/cards_50_50/public/2021-09/cart-relapse-heroart.jpg.webp?itok=aFf5G15s "Surface of an engineered T cell") 

 

###  Researchers boost understanding of T-cell therapy in blood cancer 

Novartis investigators find genetic explanations for why some young patients relapse.

 

 

 ](/stories/researchers-boost-understanding-t-cell-therapy-blood-cancer) 





 

 

 



     ![Group of production specialists in Stein](/sites/novartis_com/files/styles/banner_image_1920/public/2021-10/stein-annoucement-cell-therapy-banner.jpg?h=13bc9006&itok=VcDytWOJ "Group of production specialists in Stein") 

 



##  Expanding CAR-T manufacturing in Europe 

European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing

 [Read More](/news/expanding-car-t-manufacturing-europe-serve-more-patients "Read More")